The enhancement of the expression of death receptor 5 (DR5) partially promotes the breast cancer sensitivity to TRAIL for AMPK-related apoptosis, demonstrating an advantage in combined chemotherapies [82]. This evidence concerns the gene PRKAA2 and breast carcinoma.